SEC Filing | Attovia Therapeutics, Inc.

View:

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Frazier Life Sciences XI, L.P.

(Last)

(First)

(Middle)

FRAZIER LIFE SCIENCES MANAGEMENT, L.P.

1001 PAGE MILL RD, BUILDING 4, STE 200B

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2026

3. Issuer Name and Ticker or Trading Symbol
Attovia Therapeutics, Inc. [ ATTO ]
Foreign Trading Symbol

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	75,349	D⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A-1 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	1,749,192	0	D⁽¹⁾
Series A-2 Preferred Stock	⁽³⁾	⁽³⁾	Common Stock	1,590,175	0	D⁽¹⁾
Series B Preferred Stock	⁽⁴⁾	⁽⁴⁾	Common Stock	1,189,940	0	D⁽¹⁾
Series C Preferred Stock	⁽⁵⁾	⁽⁵⁾	Common Stock	961,322	0	D⁽¹⁾

1. Name and Address of Reporting Person^*

Frazier Life Sciences XI, L.P.

(Last)

(First)

(Middle)

FRAZIER LIFE SCIENCES MANAGEMENT, L.P.

1001 PAGE MILL RD, BUILDING 4, STE 200B

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FHMLS XI, L.P.

(Last)

(First)

(Middle)

FRAZIER LIFE SCIENCES MANAGEMENT, L.P.

1001 PAGE MILL RD, BUILDING 4, STE 200B

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

FHMLS XI, L.L.C.

(Last)

(First)

(Middle)

FRAZIER LIFE SCIENCES MANAGEMENT, L.P.

1001 PAGE MILL RD, BUILDING 4, STE 200B

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

Explanation of Responses:

1. The shares are held directly by Frazier Life Sciences XI, L.P. FHMLS XI, L.P. is the general partner of Frazier Life Sciences XI, L.P. and FHMLS XI, L.L.C. is the general partner of FHMLS XI, L.P.

2. The Series A-1 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the initial public offering of the Issuer (the "IPO"), the shares of Series A-1 Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.

3. The Series A-2 Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series A-2 Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.

4. The Series B Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series B Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.

5. The Series C Preferred Stock has no expiration date and is convertible into shares of Common Stock of the Issuer at the option of the holder. Upon closing of the IPO, the shares of Series C Preferred Stock will automatically convert into the number of shares of Common Stock of the Issuer shown in column 3.

	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.	08/04/2026
	By Jennifer Martin, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.	08/04/2026
	By Jennifer Martin, CFO of FHMLS XI, L.L.C.	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.